Alaunos Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Alaunos Therapeutics şirketinin toplam hissedar öz sermayesi $2.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $3.6M ve $826.0K dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$1.68m
Eşitlik	US$2.72m
Toplam yükümlülükler	US$826.00k
Toplam varlıklar	US$3.55m

Son finansal sağlık güncellemeleri

Recent updates

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Oct 04

Alaunos posts 51% tumor reduction for lung cancer therapy

Sep 21

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Sep 15

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Aug 31

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Aug 15

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Jul 26

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Apr 06

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Dec 20

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

Jun 19

ZIOPHARM records sharpest gain in nearly four months

Jun 09

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

Jan 14

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

Dec 21

Activist holder wins Ziopharm Oncology board seats

Dec 17

Ziopharm Oncology CFO to step down

Dec 14

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Nov 20

ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Ziopharm Oncology thumbs down on investor's call for board seats

Nov 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: TCRT 'nin kısa vadeli varlıkları ( $3.6M ) kısa vadeli yükümlülüklerini ( $826.0K ) aşıyor.

Uzun Vadeli Yükümlülükler: TCRT un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: TCRT borçsuzdur.

Borcun Azaltılması: TCRT un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: TCRT şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 11.3 oranında tarihsel oranda büyümeye devam ederse TCRT un bir yıldan az nakit akışı süresi vardır.

Alaunos Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Alaunos Therapeutics Receives a Staff Delisting Determination Letter from the Listing Qualifications Department

Nasdaq Approves Transfer of the Listing of the Common Stock of Alaunos Therapeutics from the Nasdaq Global Select Market to the Nasdaq Capital Market

Alaunos Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Recent updates

Alaunos Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue, Jr. as Interim Chief Executive Officer

Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue as Director

Alaunos Therapeutics, Inc. Announces the Resignation of Mary Thistle as Member of the Board of Directors

Alaunos Therapeutics Receives a Staff Delisting Determination Letter from the Listing Qualifications Department

Nasdaq Approves Transfer of the Listing of the Common Stock of Alaunos Therapeutics from the Nasdaq Global Select Market to the Nasdaq Capital Market

Alaunos Therapeutics Announces Presentation At the 2Nd Hawaii Global Summit on Thoracic Malignancies

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

Alaunos Therapeutics, Inc. to Report Q1, 2023 Results on May 10, 2023

Forecast to breakeven in 2025

Price target decreased to US$3.75

Alaunos Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Independent Director recently bought US$813k worth of stock

Alaunos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Alaunos Therapeutics, Inc. has completed a Follow-on Equity Offering.

High number of new and inexperienced directors

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Alaunos Therapeutics, Inc. Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos posts 51% tumor reduction for lung cancer therapy

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using Its TCR-T Cell Therapy

Price target increased to US$4.20

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Alaunos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Price target decreased to US$3.70

Alaunos Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Alaunos Therapeutics, Inc. Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

High number of new and inexperienced directors

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

ZIOPHARM Oncology, Inc.(NasdaqGS:TCRT) dropped from NASDAQ Composite Index

Consensus forecasts updated

Consensus forecasts updated

ZIOPHARM Oncology, Inc. Announces Operational Progress

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Price target decreased to US$4.60

High number of new directors

ZIOPHARM Oncology, Inc. announced delayed 10-Q filing

ZIOPHARM Oncology, Inc.(NasdaqGS:ZIOP) dropped from Russell 3000E Value Index

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

ZIOPHARM records sharpest gain in nearly four months

Chief Legal Officer & Secretary has left the company

Price target decreased to US$5.08

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

Price target decreased to US$5.08

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

CEO & Director Laurence James Cooper has left the company

Ziopharm Oncology, Inc. Receives IND Clearance by the U.S. FDA for Its TCR-T Trial Utilizing Six "Hotspot" TCRs from Its Library

Ziopharm Oncology, Inc. Appoints Timothy Cunningham Interim Chief Financial Officer

ZIOPHARM Oncology, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Ziopharm Oncology, Inc. Announces Election of Robert Postma to Board of Directors

New 90-day high: US$4.24

Ziopharm Oncology Inc. Announces Executive Changes

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

New 90-day high: US$3.16

CEO & Director notifies of intention to sell stock

Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

ZIOPHARM Oncology, Inc. Announces Executive Changes

Activist holder wins Ziopharm Oncology board seats

Ziopharm Oncology, Inc. Announces Resignation of Satyavrat Shukla as CFO

New 90-day high: US$3.09

Ziopharm Oncology CFO to step down